<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444466</url>
  </required_header>
  <id_info>
    <org_study_id>UP0086</org_study_id>
    <secondary_id>2019-002981-12</secondary_id>
    <nct_id>NCT04444466</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants</brief_title>
  <official_title>A First-In-Human, Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled, Single- and Multiple-Dose, Dose-Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess safety, tolerability and pharmacokinetics (PK) of oral&#xD;
      UCB8600.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    internal company decision; not safety related&#xD;
  </why_stopped>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Actual">August 2, 2021</completion_date>
  <primary_completion_date type="Actual">August 2, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort design</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is an investigator- and participant-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From Baseline (Day 1) until the End of Study (up to Day 42)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A treatment-emergent adverse event is characterized according to the intake of the study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The maximum plasma concentration (Cmax) of a single dose UCB8600</measure>
    <time_frame>Plasma samples will be taken predose on Day 1 and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 216 hours postdose</time_frame>
    <description>Cmax: Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax) of a single dose UCB8600</measure>
    <time_frame>Plasma samples will be taken predose on Day 1 and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 216 hours postdose</time_frame>
    <description>tmax: Time to maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve (AUC) of a single dose UCB8600</measure>
    <time_frame>Plasma samples will be taken predose on Day 1 and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 216 hours postdose</time_frame>
    <description>AUC0-infinity: Area under the plasma concentration time curve from time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum plasma concentration (Cmax) of multiple doses UCB8600</measure>
    <time_frame>Plasma samples will be taken on Day 1, 9 and 14 at: predose, 0.5, 1, 2, 3, 6, 12, 24 hours postdose</time_frame>
    <description>Cmax: Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (tmax) of multiple doses UCB8600</measure>
    <time_frame>Plasma samples will be taken on Day 1, 9 and 14 at: predose, 0.5, 1, 2, 3, 6, 12, 24 hours postdose</time_frame>
    <description>tmax: Time to maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve (AUCtau) over a dosing interval on Day 1 of multiple doses UCB8600</measure>
    <time_frame>Plasma samples will be taken on Day 1 at: predose, 0.5, 1, 2, 3, 6, 12, 24 hours postdose</time_frame>
    <description>AUCtau: Area Under the Curve over a dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve (AUCtau) over a dosing interval on Day 9 of multiple doses UCB8600</measure>
    <time_frame>Plasma samples will be taken on Day 9 at: predose, 0.5, 1, 2, 3, 6, 12, 24 hours postdose</time_frame>
    <description>AUCtau: Area Under the Curve over a dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve (AUCtau) over a dosing interval on Day 14 of multiple doses UCB8600</measure>
    <time_frame>Plasma samples will be taken on Day 14 at: predose, 0.5, 1, 2, 3, 6, 12, 24 hours postdose</time_frame>
    <description>AUCtau: Area Under the Curve over a dosing interval</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Study Participants</condition>
  <condition>Chronic Spontaneous Urticaria</condition>
  <arm_group>
    <arm_group_label>UCB8600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants randomized to this arm will receive various single doses and multiple doses of UCB8600 administered to various cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study participants randomized to this arm will receive various single doses and multiple doses of Placebo administered to various cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB8600</intervention_name>
    <description>Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.</description>
    <arm_group_label>UCB8600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study participants will receive Placebo in a pre-specified sequence during the Treatment Period matching UCB8600.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Applicable to Parts A-D&#xD;
&#xD;
          -  Participant must be 18 to 65 years of age inclusive, at the time of signing the&#xD;
             informed consent&#xD;
&#xD;
          -  Participants who are overtly healthy (in the opinion of the investigator) as&#xD;
             determined by medical evaluation including medical history (any chronic and acute&#xD;
             illness), physical examination, vital signs, 12-lead electrocardiogram (ECG), and&#xD;
             laboratory screening tests at the Screening Visit&#xD;
&#xD;
          -  Body weight 45 kg or greater and body mass index (BMI) within the range 19 and 30&#xD;
             kg/m^2 (inclusive)&#xD;
&#xD;
        Part B-specific&#xD;
&#xD;
          -  Study participants must have a Screening serum immunoglobulin E (IgE) of ≥30 kU/L and&#xD;
             ≤700 kU/L for inclusion in Cohort 1 through Cohort 4a and &gt;700 kU/L for inclusion in&#xD;
             Cohort 4b&#xD;
&#xD;
          -  Study participants must be documented to be sensitized to at least 1 common&#xD;
             aeroallergen confirmed by (skin prick test (SPT) at Screening)&#xD;
&#xD;
        Part C-specific&#xD;
&#xD;
          -  Study participants must have a diagnosis of chronic spontaneous urticaria (CSU)&#xD;
             diagnosed by a dermatologist, allergist or clinical immunologist and have persistent&#xD;
             symptoms most days of the week for the last 6 weeks despite regular use of an H1&#xD;
             antihistamine according to the EAACI/GA²LEN/EDF/WAO guideline&#xD;
&#xD;
          -  Study participants must have a documented 7-day Urticaria Assessment Score (UAS7)&#xD;
             score of 16 or above and an 7-day Itch Severity Score (ISS7) of 8 or above at Visit 2&#xD;
             (Day -1, Admission)&#xD;
&#xD;
          -  Study participants must have a Screening serum immunoglobulin E (IgE) of ≥30 kU/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Applicable to Parts A-D&#xD;
&#xD;
          -  Participant has any (acute or chronic [including severe acute respiratory syndrome&#xD;
             coronavirus 2 (SARS-CoV-2) infection]) medical or psychiatric condition that, in the&#xD;
             opinion of the investigator, could jeopardize or would compromise the study&#xD;
             participant's ability to participate in this study&#xD;
&#xD;
          -  Study participant has 12-lead electrocardiogram (ECG) with changes considered to be&#xD;
             clinically significant (eg, QT interval corrected using Fridericia's formula (QTcF)&#xD;
             &gt;450 msec , left bundle branch block, or evidence of myocardial ischemia) at the&#xD;
             Screening Visit or Day -1 (Admission)&#xD;
&#xD;
          -  A history of additional risk factors for Torsades de pointes (TdP) (eg, heart failure,&#xD;
             hypokalemia, family history of Long QT Syndrome)&#xD;
&#xD;
          -  Study participant has a history of atopy, allergic rhinitis, urticaria, angioedema,&#xD;
             asthma, food allergies, or anaphylaxis&#xD;
&#xD;
          -  Study participant has a known hypersensitivity to any components of the study&#xD;
             medication or comparative drugs as stated in this protocol&#xD;
&#xD;
          -  Study participant has a history of drug allergy or other allergy that, in the opinion&#xD;
             of the investigator or UCB Study Physician, contraindicates his/her participation.&#xD;
&#xD;
          -  Study participants with evidence of helminthic parasitic infection as evidenced by&#xD;
             stools being positive for a pathogenic organism according to local guidelines. All&#xD;
             participants will be screened at Screening. If stool testing is positive for&#xD;
             pathogenic organism, the participants will not enter Treatment Period and will not be&#xD;
             allowed to rescreen&#xD;
&#xD;
          -  Study participant has received prescription or nonprescription medicines (including&#xD;
             over-the-counter medicines and herbal and dietary supplements [including St John's&#xD;
             Wort]) that have been taken within 14 days prior to Screening. Drugs that are strong&#xD;
             or moderate inhibitors or inducers of cytochrome P450 (CYP)3A4 and/or P-glycoprotein&#xD;
             (Pgp) are prohibited&#xD;
&#xD;
          -  The use of concomitant medications that prolong the QT/QTc interval&#xD;
&#xD;
          -  Study participant has donated more than 500 mL of blood or blood products within 90&#xD;
             days prior to Admission (Day -1) or plans to donate blood during the study (20 weeks&#xD;
             post Screening)&#xD;
&#xD;
          -  Study participant has consumed any grapefruit, grapefruit juice, grapefruit-containing&#xD;
             products, or star fruit within 14 days prior to administration of UCB8600&#xD;
&#xD;
        Part B-specific&#xD;
&#xD;
          -  Study participant has:&#xD;
&#xD;
               1. a history of angioedema, severe asthma, severe food allergies, or anaphylaxis&#xD;
&#xD;
               2. a personal or family history of cardiomyopathy&#xD;
&#xD;
          -  A Screening forced expiratory volume (FEV1) &lt;80% predicted (highest of 3)&#xD;
&#xD;
          -  Study participant has:&#xD;
&#xD;
               1. Allergen immunotherapy, also known as desensitization or hyposensitization at a&#xD;
                  maintenance licensed dose (depending on the type of immunotherapy [subcutaneous&#xD;
                  or sublingual]) for ≥3 months prior to Screening and then throughout the study&#xD;
&#xD;
               2. Severe positive reaction to Screening skin prick test&#xD;
&#xD;
          -  Topical or systemic corticosteroids, including high dose oral (&gt;5 mg prednisolone), in&#xD;
             the past 14 days prior to Screening and throughout the study&#xD;
&#xD;
          -  Topical immunosuppressants in the past 14 days prior to Screening and throughout the&#xD;
             study&#xD;
&#xD;
          -  Tricyclic antidepressants, prescription antihistamines, over-the-counter&#xD;
             antihistamines, and heartburn medications in the past 14 days prior to Admission&#xD;
&#xD;
          -  Systemic immunosuppressants such as azathioprine, methotrexate, cyclosporine, and&#xD;
             mycophenolate mofetil in the past 4 weeks prior to Screening and throughout the study&#xD;
&#xD;
          -  Biologics such as omalizumab for the past 6 months prior to Screening and throughout&#xD;
             the study&#xD;
&#xD;
        Part C-specific&#xD;
&#xD;
          -  Study participant has:&#xD;
&#xD;
               1. a history of angioedema, severe asthma, severe food allergies, or anaphylaxis&#xD;
&#xD;
               2. a personal or family history of cardiomyopathy&#xD;
&#xD;
          -  Study participants with a serum IgE level of &gt;1000 kU/L&#xD;
&#xD;
          -  A screening FEV1 &lt;80% predicted (average of 3)&#xD;
&#xD;
          -  Allergen immunotherapy, also known as desensitization or hyposensitization at a&#xD;
             maintenance licensed dose (depending on the type of immunotherapy [subcutaneous or&#xD;
             sublingual]) for ≥3 months prior to Screening and then throughout the study&#xD;
&#xD;
          -  Topical or systemic corticosteroids, including high dose oral (&gt;5 mg prednisolone), in&#xD;
             the past 14 days prior to Screening and throughout the study&#xD;
&#xD;
          -  Topical immunosuppressants in the past 14 days prior to Screening and throughout the&#xD;
             study&#xD;
&#xD;
          -  Systemic immunosuppressants such as azathioprine, methotrexate, cyclosporine, and&#xD;
             mycophenolate mofetil in the past 4 weeks prior to Screening and throughout the study&#xD;
&#xD;
          -  Biologics such as omalizumab for the past 6 months prior to Screening and throughout&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Up0086 001</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy study participants</keyword>
  <keyword>UCB8600</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Chronic spontaneous urticaria</keyword>
  <keyword>CSU</keyword>
  <keyword>IgE</keyword>
  <keyword>Atopic participants</keyword>
  <keyword>Urticaria</keyword>
  <keyword>UCB</keyword>
  <keyword>Food Effect (Part D)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

